Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5355137 | 0.84 | HTR2C (0.52) | HTR2CHTR2BMAPTRAB9A | |
| SCHEMBL5361852 | 0.83 | TGM2 (0.52) | GAAALDH1A1 | |
| SCHEMBL30555216 | 0.82 | HTR2C (0.61) | GAAALDH1A1HTR2CHTR2BMAPT | |
| SCHEMBL1156335 | 0.82 | HTR2C (0.68) | GAAHTR2CHTR2BMAPTCA12 | |
| SCHEMBL31130054 | 0.82 | HTR2C (0.68) | GAAHTR2CHTR2BMAPTCA12 | |
| SCHEMBL1155852 | 0.78 | MEN1 (0.55) | MAPTNPC1RAB9AKMT2A | |
| SCHEMBL29736947 | 0.78 | EPHX2 (0.48) | GAAALDH1A1MAPTCA12CA1 | |
| SCHEMBL23246088 | 0.77 | GAA (0.47) | GAAALDH1A1MAPTKMT2A | |
| SCHEMBL31454312 | 0.77 | LMNA (0.52) | ALDH1A1HTR2CHTR2BMAPTRAB9A | |
| SCHEMBL23260601 | 0.76 | PKM (0.59) | GAAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101884-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050070546-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| WO-2003024969-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070546-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | GAA 1166/4885ALDH1A1 3104/4885HTR2C 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.